Modulation of Cellular Redox Parameters for Improving Therapeutic Responses in Multiple Myeloma

Overview

Journal Antioxidants (Basel)

Date 2022 Mar 25

PMID 35326105

Authors

Alessandro Allegra

Claudia Petrarca

Mario Di Gioacchino

Marco Casciaro

Caterina Musolino

Sebastiano Gangemi

Affiliations

Soon will be listed here.

Abstract

Raised oxidative stress and abnormal redox status are typical features of multiple myeloma cells, and the identification of the intimate mechanisms that regulate the relationships between neoplastic cells and redox homeostasis may reveal possible new anti-myeloma therapeutic targets to increase the effectiveness of anti-myeloma drugs synergistically or to eradicate drug-resistant clones while reducing toxicity toward normal cells. An alteration of the oxidative state is not only responsible for the onset of multiple myeloma and its progression, but it also appears essential for the therapeutic response and for developing any chemoresistance. Our review aimed to evaluate the literature's current data on the effects of oxidative stress on the response to drugs generally employed in the therapy of multiple myeloma, such as proteasome inhibitors, immunomodulators, and autologous transplantation. In the second part of the review, we analyzed the possibility of using other substances, often of natural origin, to modulate the oxidative stress to interfere with the progression of myelomatous disease.

Citing Articles

Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients.

Plakoula E, Kalampounias G, Alexis S, Verigou E, Kourakli A, Zafeiropoulou K Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852147 PMC: 11763810. DOI: 10.3390/cimb47010032.

Multiple Myeloma from the Perspective of Pro- and Anti-Oxidative Parameters: Potential for Diagnostic and/or Follow-Up Purposes?.

Kul A, Ozturk Kurt B J Pers Med. 2024; 14(3).

PMID: 38540964 PMC: 10971040. DOI: 10.3390/jpm14030221.

Protective Effects of High-Density Lipoprotein on Cancer Risk: Focus on Multiple Myeloma.

Allegra A, Murdaca G, Mirabile G, Gangemi S Biomedicines. 2024; 12(3).

PMID: 38540127 PMC: 10967848. DOI: 10.3390/biomedicines12030514.

The Interplay between Medical Plants and Gut Microbiota in Cancer.

Caserta S, Genovese C, Cicero N, Toscano V, Gangemi S, Allegra A Nutrients. 2023; 15(15).

PMID: 37571264 PMC: 10421419. DOI: 10.3390/nu15153327.

The Anti-Cancer Effect of Cinnamon Aqueous Extract: A Focus on Hematological Malignancies.

Caserta S, Genovese C, Cicero N, Gangemi S, Allegra A Life (Basel). 2023; 13(5).

PMID: 37240821 PMC: 10222973. DOI: 10.3390/life13051176.

References

Dvorakova K, Payne C, Tome M, Briehl M, McClure T, Dorr R . Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Biochem Pharmacol. 2000; 60(6):749-58. DOI: 10.1016/s0006-2952(00)00380-4. View

Schonfeld P, Wojtczak L . Fatty acids as modulators of the cellular production of reactive oxygen species. Free Radic Biol Med. 2008; 45(3):231-41. DOI: 10.1016/j.freeradbiomed.2008.04.029. View

Xu J, Timares L, Heilpern C, Weng Z, Li C, Xu H . Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res. 2010; 70(16):6566-76. PMC: 2922473. DOI: 10.1158/0008-5472.CAN-10-0942. View

Arihara Y, Takada K, Kamihara Y, Hayasaka N, Nakamura H, Murase K . Small molecule CP-31398 induces reactive oxygen species-dependent apoptosis in human multiple myeloma. Oncotarget. 2017; 8(39):65889-65899. PMC: 5630380. DOI: 10.18632/oncotarget.19508. View

Anchoori R, Tan M, Tseng S, Peng S, Soong R, Algethami A . Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties. PLoS One. 2020; 15(1):e0227727. PMC: 6961910. DOI: 10.1371/journal.pone.0227727. View

Samovski D, Kalderon B, Yehuda-Shnaidman E, Bar-Tana J . Gating of the mitochondrial permeability transition pore by long chain fatty acyl analogs in vivo. J Biol Chem. 2009; 285(10):6879-90. PMC: 2844138. DOI: 10.1074/jbc.M109.080416. View

Dvorakova K, Waltmire C, Payne C, Tome M, Briehl M, Dorr R . Induction of mitochondrial changes in myeloma cells by imexon. Blood. 2001; 97(11):3544-51. DOI: 10.1182/blood.v97.11.3544. View

Imam F, Al-Harbi N, Al-Harbi M, Ansari M, Almutairi M, Alshammari M . Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats. Toxicol Mech Methods. 2016; 26(9):700-708. DOI: 10.1080/15376516.2016.1236425. View

Zhang X, Espinosa B, Saei A, Darcy P, Zubarev R, Linder S . Oxidative Stress Induced by the Deubiquitinase Inhibitor b-AP15 Is Associated with Mitochondrial Impairment. Oxid Med Cell Longev. 2019; 2019:1659468. PMC: 6590552. DOI: 10.1155/2019/1659468. View

10.

Weille J, Fabre C, Bakalara N . Oxysterols in cancer cell proliferation and death. Biochem Pharmacol. 2013; 86(1):154-60. DOI: 10.1016/j.bcp.2013.02.029. View

11.

Imbesi S, Musolino C, Allegra A, Saija A, Morabito F, Calapai G . Oxidative stress in oncohematologic diseases: an update. Expert Rev Hematol. 2013; 6(3):317-25. DOI: 10.1586/ehm.13.21. View

12.

Allegra A, Innao V, Polito F, Oteri R, Alibrandi A, Allegra A . SIRT2 and SIRT3 expression correlates with redox imbalance and advanced clinical stage in patients with multiple myeloma. Clin Biochem. 2021; 93:42-49. DOI: 10.1016/j.clinbiochem.2021.04.002. View

13.

Allegra A, Speciale A, Molonia M, Guglielmo L, Musolino C, Ferlazzo G . Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways. Toxicol In Vitro. 2017; 47:186-194. DOI: 10.1016/j.tiv.2017.12.001. View

14.

Mehdi W, Zainulabdeen J, Mehde A . Investigation of the antioxidant status in multiple myeloma patients: effects of therapy. Asian Pac J Cancer Prev. 2013; 14(6):3663-7. DOI: 10.7314/apjcp.2013.14.6.3663. View

15.

Liu C, Liu Z, Li M, Li X, Wong Y, Ngai S . Enhancement of auranofin-induced apoptosis in MCF-7 human breast cells by selenocystine, a synergistic inhibitor of thioredoxin reductase. PLoS One. 2013; 8(1):e53945. PMC: 3544722. DOI: 10.1371/journal.pone.0053945. View

16.

Fang Q, Jiang S, Li C . Evodiamine Selectively Inhibits Multiple Myeloma Cell Growth by Triggering Activation of Intrinsic Apoptosis Pathway. Onco Targets Ther. 2020; 12:11383-11391. PMC: 6935306. DOI: 10.2147/OTT.S235730. View

17.

No J, Kim Y, Song Y . Targeting nrf2 signaling to combat chemoresistance. J Cancer Prev. 2014; 19(2):111-7. PMC: 4204167. DOI: 10.15430/JCP.2014.19.2.111. View

18.

Taniguchi N, Osaki M, Onuma K, Ishikawa M, Ryoke K, Kodani I . Bisphosphonate-induced reactive oxygen species inhibit proliferation and migration of oral fibroblasts: A pathogenesis of bisphosphonate-related osteonecrosis of the jaw. J Periodontol. 2019; 91(7):947-955. DOI: 10.1002/JPER.19-0385. View

19.

Goel A, Spitz D, Weiner G . Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma. J Cell Biochem. 2011; 113(2):419-25. PMC: 3374635. DOI: 10.1002/jcb.23387. View

20.

Jhaveri K, Wanchoo R . Carfilzomib-induced nephrotoxcity. Kidney Int. 2015; 88(1):199-200. DOI: 10.1038/ki.2015.133. View